Darmstadt (Free subscription) | 08/10/2009
EMD Serono Inc., a Rockland-based biopharmaceutical firm, has joined The University of Texas M.D. Anderson Cancer Center in forming a three-year, non-exclusive collaboration. The agreement ...
Fiercebiotech (Free subscription) | 03/23/2009
Merck Serono, a division of Germany's Merck KGaA, has set aside $55 million for a new venture fund that will invest in start-up biotech companies at a time many developers are starving for cash. And Merck Serono Ventures will keep its sights fixed firmly on new biotech companies that could prove instrumental in advancing therapies for its core focus: neurodegenerative diseases, oncology and autoimmune...
PR News Wire (Free subscription) | 03/23/2009
GENEVA, March 23 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the formation of 'Merck Serono Ventures', a strategic, corporate venture capital fund to invest in emerging biotechnology companies. The fund will support biotech start-up companies that have the potential to provide innovative products in Merck Serono's core therapeutic areas, in particular...
PR News Wire (Free subscription) | 03/18/2009
Choose links below to browse the latest Industry News and related resources from PR Newswire.
Fiercebiotech (Free subscription) | 03/18/2009
Merck KGaA is funneling $19 million into a joint research project between one of its subsidiaries--EMD Serono--and the National Multiple Sclerosis Society to fast-track new therapies for MS. The deal starts as a two-year R&D pact with an option to extend it by another three years. Under the deal, EMD Serono will join hands with Fast Forward, a subsidiary of the MS Society that partners on new...
Swisster (Free subscription) | 03/17/2009
Ernesto Bertarelli, patron of the Alinghi yacht team, is bailing out from the board of UBS bank along with two other members in the latest executive shakeup at Switzerland's largest bank. Bertarelli, a former owner of the Serono biotech company and regarded as the wealthiest Swiss man in the country, is stepping down next month after seven years on the board. He leaves after the bank recorded the worst...
Medical News Today (Free subscription) | 03/16/2009
Merck Serono announced the launch of its Phase II clinical study CERTOa, which will investigate the efficacy and safety of the novel combination of the investigational integrin inhibitor, cilengitide, and Erbitux® (cetuximab), with cisplatin and either vinorelbine or gemcitabine, as 1st-line treatment for patients with advanced non-small cell lung cancer (NSCLC).
Market Wire (Free subscription) | 02/23/2009
MISSISSAUGA, ONTARIO (MARKET WIRE) Based on a recommendation by Health Canada, EMD Serono Canada Inc., the Canadian affiliate of Merck Serono(1) who markets Raptiva(R) in Canada, is suspending Raptiva(R) from the Canadian marketplace due to safety concerns, including the occurrence of Progressive Multifocal Leukoencephalopathy (PML) in patients taking this medication. In Canada, Raptiva(R) is indicated...
Medical News Today (Free subscription) | 02/20/2009
The European Medicines Agency (EMEA) has recommended the suspension of the marketing authorisation for Raptiva (efalizumab), from Serono.
Canadian Online Health News (Free subscription) | 02/20/2009
TORONTO - The distributor of a psoriasis drug that is the subject of safety concerns has agreed to suspend sales of the medication in Canada. Health Canada recommended that EMD Serono Canada Inc. stop the marketing of Raptiva, the brand name for the drug efalizumab.
Business Wire (Free subscription) | 02/17/2009
LYON, France--(BUSINESS WIRE)--Flamel Technologies (NASD: FLML) announced today that it has entered into a full license agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, to apply Flamel’s
Medical News Today (Free subscription) | 02/04/2009
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA (SWX: NWRN), announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours. "ON"...
Life Science World (Free subscription) | 02/03/2009
[NEWS] GENEVA, Feb. 3 /PRNewswire/ — — The Six-Month Primary Efficacy Endpoint of the Study was met: Both Doses of Investigational Agent Safinamide Significantly Increased “ON” Time in Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease — Secondary Efficacy Endpoints of the Study Analyzed to Date Were met in Both Safinamide Dose Groups Merck Serono, a...
Videos